99m Tc-Labeled-rhTSH Analogue (TR1401) for Imaging Poorly Differentiated Metastatic Thyroid Cancer

Abstract

Background:

Differentiated thyroid carcinomas originating from thyroid follicular cells are frequent tumors of the thyroid with relatively good prognosis due to improved surgical techniques and follow-up procedures. Poorly differentiated thyroid cancers, which lose iodine uptake ability, in most cases still express thyrotropin (TSH) receptors (TSHR). Therefore, the aim of this study was to radiolabel a superagonist recombinant human TSH (rhTSH) analogue for imaging poorly differentiated thyroid cancer.

Methods:

The TSHR superagonist, TR1401, was labeled with ^99mTc using an indirect method via succinimidyl-6-hydrazinonicotinate hydrochloride conjugation. In vitro quality controls included SDS-PAGE, cysteine challenge, and cell-binding assay on TSHR positive cell lines (JP09 and ML-1). In vivo studies included tumor targeting experiments in athymic nude CD-1 mice xenografted with several different TSHR positive cells (JP09, K1, and ML-1) and TSHR negative cells (JP02) as control.

Results:

The superagonist rhTSH analogue TR1401 was labeled with high labeling efficiency (>95%) and high specific activity (9250 MBq/mg). The labeled molecule retained its biologic activity and structural integrity. In tumor targeting experiments, a focal uptake of radiolabeled TR1401 was observed in TSHR positive cells but not in TSHR negative cells. The same observation was made in a dog with spontaneous intraglandular thyroid cancer.

Conclusions:

We were able to radiolabel the rhTSH superagonist analogue TR1401 with ^99mTc efficiently with retention of in vitro and in vivo binding capacity to TSHR. The relative role of such novel radiopharmaceutical versus ¹³¹I scanning of thyroid cancer will require future histopathologic and clinical studies, but it may open new perspectives for presurgical staging of thyroid cancer, and diagnosis of radioiodine negative local relapses and/or distant metastases.

Introduction

Papillary and follicular thyroid carcinomas are usually well-differentiated tumors that retain in part the biologic characteristics of normal thyroid follicular cells. Under thyrotropin (TSH) stimulation, metastases take up radioiodine through the sodium/iodide symporter (NIS), synthesize, and release thyroglobulin (Tg) (1). Thyroid cancer cells retain the capacity of synthesizing thyroid peroxidase (TPO) and, in particular, the TSH receptor (TSHR) that is expressed on the basolateral membrane (2,3), which is essential for stimulation through TSH for ¹³¹I scanning and therapy, measurement of stimulated Tg levels, and, in some cases, (¹⁸F)-Fluoro-deoxy-glucose (FDG) positron-emission tomography (PET) imaging. The incidence of differentiated thyroid cancers originating from thyroid follicular cells has increased significantly since 1983 (4), not only because of the improvement of detection techniques, but also because of an increase in risk factors. Approximately 10–15% of differentiated thyroid cancers lose NIS expression and the capacity to iodine uptake, but they still retain the ability to express the TSHR and Tg (5). The loss of NIS is often caused by a de-differentiation or, because of the genetic instability of cancer cells, NIS-deficient clones may survive after radioiodine therapy and cause distant metastases that are not radioiodine avid. These cancers may or may not produce Tg, and are classified as poorly differentiated or undifferentiated thyroid cancers and require different diagnostic and therapeutic approaches compared to typical differentiated thyroid cancers. The diagnosis of local recurrences or distant metastases in differentiated thyroid cancers is routinely performed after total thyroidectomy, under conditions of hypothyroidism, or after stimulation induced by wild-type recombinant human TSH (rhTSH; Thyrogen^®) to obtain an increase of TSH levels and stimulate NIS expression and Tg production (6). This is followed by the administration of a diagnostic dose of 74–370 MBq of ¹³¹I and a whole body scan (WBS) to detect thyroid remnants, local residual or recurrent disease, and/or distant metastases. Demonstration of residual disease on ¹³¹I-WBS is the basis on which to perform therapy with high doses of ¹³¹I. This approach has been used in the last decades with few modifications, and significantly prolongs the survival of patients with well-differentiated thyroid cancer (7,8). Interestingly, a minority of patients with a negative diagnostic ¹³¹I-WBS (dWBS) can still show iodine uptake by metastases, as confirmed by positivity on post-therapy ¹³¹I-WBS (tWBS) or positivity on diagnostic ¹²⁴I-PET scans (9 –11).

In patients with poorly differentiated thyroid cancer with low or no iodine uptake (either ¹²⁴I or ¹³¹I) but with high Tg values, a PET scan with [¹⁸F]-FDG can be performed for staging (12,13). This often allows the detection of residual disease and enables surgery to be planned in selected cases. In most cases of poorly differentiated thyroid cancer, however, there is no satisfactory therapy to date, despite recent attempts using tyrosine kinase inhibitors (14).

PET scanning with [¹⁸F]-FDG has also shown a higher diagnostic accuracy when performed in hypothyroidism or after rhTSH administration, indicating that poorly differentiated thyroid cancers still express TSHR despite loss of NIS (15). The expression of other receptors has been correlated with the degree of cell differentiation, such as, for example, the somatostatin and VEGF receptors (VEGFR) (16 –19). Therefore, it appears that a wide range of differentiation can occur in thyroid cancer cells from well-differentiated ones, expressing NIS, TSHR, making Tg, and expressing low levels of glucose transporters (GLUTs), to non-differentiated cancer cells with complete loss of NIS and low production of Tg but high expression of glucose transporters, TSHR, and VEGFR (5,20).

Given this wide range of de-differentiation characteristics, it is relevant to develop new diagnostic tools for the in vivo characterization of thyroid-derived lesions, with the aim of performing better staging and follow-up evaluations in order to select the most appropriate therapy.

In the present study, we describe the radiolabeling with ^99mTechnetium (^99mTc) of a new superagonist rhTSH analogue to produce a new radiopharmaceutical for single photon emission computed tomography (SPECT) imaging of differentiated and poorly differentiated thyroid cancer.

We selected the analogue TR1401 (21,22) whose sequence mainly differs from hTSH by four additional positively charged amino acids located in close spatial proximity at the α-L1 loop, of which three are located at identical positions in bovine TSH (bTSH). Such positive charges are involved in receptor binding, increasing the affinity of TR1401 (and bTSH) for the TSHR, as revealed by increased cAMP signaling. Specific negatively charged amino acids in the hinge region of the TSHR have been implicated as mediators of the superagonistic activity of TR1401 as compared to the wild-type rhTSH (21).

Materials and Methods

Labeling of superagonist rhTSH analogue TR1401 with ^99mTc

The human rhTSH analogue TR1401 was produced at Trophogen, Inc., by site-directed mutagenesis techniques in stably transfected Chinese Hamster Ovary (CHO) cells, and purified by a combination of dye, ion exchange, and gel filtration high-performance liquid chromatography (HPLC). The TR1401 molecule contains four lysine substitutions (Q13K+E14K+P16K+Q20K) in the α subunit of the glycoprotein in comparison to the wild-type molecule (21 –23).

Indirect labeling of the highly purified TR1401 molecule was performed by conjugation with the bifunctional chelator succinimidyl-6-hydrazinonicotinate hydrochloride (HYNIC), which is able to bind both proteins and ^99mTc. The analogue was modified by conjugation with SHNH (SoluLink) in dimethylformamide (DMF; Sigma-Aldrich Chemical) and purified from free SHNH by G-25 Sephadex PD10 column (GE Healthcare) using nitrogen-purged phosphate buffer saline (pH 7.4) as an eluant. In order to identify the best labeling conditions, 40 μg TR1401 (in 100 μL phosphate-buffered saline (PBS)) was labeled with 370 MBq of freshly eluted ^99mTcO₄ ⁻ (100 μL) in the presence of 200 μL tricine (Sigma-Aldrich; from 0.9 mg/mL to 200 mg/mL PBS) and 5 μL SnCl₂ (Sigma-Aldrich; from 2 mg/mL to 20 mg/mL 0.1 M HCl). The reaction volume was always 405 μL. Labeling efficiency (LE) and colloid percentages were measured after 10, 30, and 60 min. After labeling, an additional purification by size exclusion chromatography was performed using a PD10 column (GE Healthcare). Free pertechnetate, tricine, and SnCl₂ were eluted with the flow-through.

The number of HYNIC groups bound per molecule of TR1401 was determined by molar substitution ratio (MSR) assay. Briefly, 2 μL of conjugated TR1401 was added to 18 μL of a 0.5 mM solution of 2-sulfobenzaldehyde in 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES) buffer, pH 5.0, and incubated at room temperature for 2 h. PBS alone was used as blank, and duplicates were prepared. After 2 h, the absorbance at 345 nm (A₃₄₅) of each reaction was measured with a spectrophotometer, and the number of HYNIC groups per molecule was calculated as indicated in the SoluLink data sheet.

In vitro quality controls

Quality controls were performed using both instant thin-layer chromatography-silica gel (ITLC-SG) strip (Pall Life Sciences) and thin-layer chromatography silica gel (TLC-SG) plates (J.T. Baker). Results were analyzed by a radio-scanner (Bioscan, Inc.) to calculate the LE of ^99mTc-HYNIC-TR1401. The mobile phase for LE determination was a 0.9% NaCl solution, whereas for colloid determination it was a NH₃:H₂O:EtOH (1:5:3) solution. Quality controls were performed before and after an additional purification step with a PD10 column. Stability assays were performed adding 100 μL of ^99mTc-HYNIC-TR1401 to 900 μL of fresh human blood serum or to 900 μL of 0.9% NaCl solution. The vials were incubated for up to 24 h at 37°C in a water bath. The radiochemical purity was measured at 1, 3, 6, and 24 h by ITLC analysis. In addition, a cysteine challenge assay was performed, incubating the labeled TR1401 at 37°C for 60 min with different cysteine concentration, ranging from 1000:1 (cysteine:TR1401) to 0.1:1 molar ratio. For each time point, radiochemical purity was evaluated by ITLC as described above. All known chemical forms of ^99mTc-cysteine have R _f values between 0.5 and 1, when normal saline was used as mobile phase. Integrity of the labeled TR1401 molecule was also checked by SDS-PAGE electrophoresis carried out according to Laemmli's method (24) on a 15% polyacrylamide gel under nonreducing conditions. Proteins were visualized by staining the gels with Coomassie Brilliant Blue (Pierce). Radioactivity associated with each band was determined scanning the gel with a radio scanner.

Cell lines and FACS analysis

Chinese hamster ovary (CHO) JP09 and JP02 cell lines (25,26) were cultured in complete Ham's F12 medium (Eurobio Laboratories) with 10% fetal calf serum (FCS; Gibco), 100 IU/mL penicillin, 100 μg/mL streptomycin, and 2 mM l-glutamine at 37°C in a 5% CO₂ atmosphere. JP09 cells were transfected with the cDNA encoding the human TSHR and were reported to express up to 100,000 receptors per cell (25,26). JP02 transfected with an empty vector were used for negative controls (25,26). Human ML-1 cells (27), deriving from differentiated thyroid cancer, were cultured in complete Dulbecco's modified Eagle's medium (DMEM) containing 100 μM sodium pyruvate, 2 mM l-glutamine, 1 mg/mL glucose, and 3.7 g/L NaHCO₃, supplemented with 10% FCS, 100 IU/mL penicillin, and 100 μg/mL streptomycin. These cells express approximately 10,000 receptors per cell (data provided by B.W.). K1 cells, expressing 10,000–100,000 receptors/cell (28) were grown in 1:1 mixture of DMEM high glucose (Gibco) and Kaighn's F12 (Gibco), both supplemented with 10% FCS, 100 IU/mL penicillin, 100 μg/mL streptomycin, and 2 mM l-glutamine.

TSHR expression was analyzed in JP09, JP02, ML-1, and K1 cell lines by immunofluorescence staining and cytofluorimetric analysis. Experiments were repeated twice. Briefly, one million cells were seeded in Eppendorf vials and incubated for 15 min with 10% inactivated murine serum in PBS at 4°C. At the end of the incubation, 10 μL of a PE-conjugated anti-TSHR antibody (Santa-Cruz) was added. Vials were incubated at 4°C for 30 min before the cells were analyzed by cytofluorimeter.

In vitro binding studies

Measurements of cell uptake and retention of labeled TR1401 was performed in vitro using a semi-automatic system: LigandTracer^™ (Ridgeview Instruments AB) (29). Briefly, 10⁶ mL⁻¹ cells were seeded in a tilted Petri dish and incubated in a humidified incubator at 37°C and 5% CO₂ for 24 h. The dish was then placed in the LigandTracer and allowed to rotate continuously for 15 min to allow weakly attached cells to detach. After one gentle wash, 2 mL of 30 nM radiolabeled TR1401 was added to the cell culture medium, and the dish rotated for 1 h. The device was then stopped, and the liquid was removed and replaced with culture medium without labeled TR1401 for calculating the release of radioactivity from the cells. Additionally, the medium was counted over time to evaluate the duration of the signal from internalized ^99mTc-HYNIC-TR1401. A binding/release curve was obtained, and data were analyzed with GraphPad Prism (GraphPad Software, Inc.) for calculating k _on, k _off, and K _d values.

For binding assay with JP09 cells that do not stably adhere to Petri dishes (30), a standard saturation binding assay was performed, as described elsewhere (31). Briefly, 3×x10⁶ cells were placed in triplicate in Eppendorf vials and incubated with decreasing concentrations of labeled TR1401 for 1 h at 4°C to calculate the total binding curve. The same experiment was performed adding a 100-fold molar excess of unlabeled TR1401 to each vial, to calculate nonspecific binding. At the end of the incubation time, the cells were washed twice with 0.5 mL of PBS. Cell pellets and the supernatants were counted separately in a single-well gamma counter (Gammatom). Nonlinear regression analysis was performed using GraphPad Prism.

In vivo high-resolution imaging

A high-resolution portable mini-gamma camera (HRC), IP-Guardian (Li-tech S.r.l.) was used as previously described (32,33). It is composed of a crystal-collimator structure coupled to a Hamamatsu H8500 Position Sensitive Photo Multiplier Tube (PSPMT), a charge readout electronics, and a data-acquisition system. The system allows real-time acquisitions to be performed with a refresh time of 0.5 s. The HRC energy resolution is about 20% at 140 keV (^99mTc), the sensitivity is 210 cps/MBq, and the uniformity is±5%, while it provides 2.2 mm intrinsic resolution suitable for imaging experiments in vivo in small animals.

For in vivo biodistribution studies, 5.5 MBq (100 μL) of labeled TR1401 was injected in the tail vein of 12 nude CD-1 mice, and static planar posterior images were acquired using the HRC at 1, 3, 6, and 24 h, under light ether anesthesia. At the end of each imaging point, three mice were sacrificed, and major organs were collected and counted in a single-well gamma counter. Time–activity curves in organs were created for both in vitro and ex vivo data.

For in vivo cell-targeting studies, we studied 12 nude CD-1 mice divided into four groups (three mice per group). Each group was injected subcutaneously with a different cell line. Cells—8×10⁶ JP09, K1, ML-1, or JP02—were mixed with BD Matrigel (BD Biosciences; 1:1) and injected subcutaneously into the right thigh; the same volume of BD Matrigel alone was injected into the left thigh as control. Approximately 1 h after cell injection, 5.5 MBq of labeled TR1401 were administered intravenously (i.v.), and static planar posterior HRC images were acquired at 1, 3, 6, and 24 h under light ether anesthesia.

In another set of experiments, three groups of three nude CD-1 mice were injected in the right thigh with 2×10⁶ JP09, ML-1, or K1 cells. In the first group, 2×10⁶ TSHR negative JP02 cells were also injected in the left thigh. After consistent tumor growth (approximately 0.6–1 cm³ in 20 days), mice were injected i.v. with 5.5 MBq of labeled TR1401, and static HRC images were acquired at 1, 3, 6, and 24 h under light ether anesthesia. All images were acquired positioning the HRC over the back of the mouse, in contact with it, for 60 s per image.

Case study in a Dachshund dog with spontaneous thyroid cancer

A seven-year-old castrated Dachshund with a visible, palpable cervical mass (about 3 cm in diameter) was selected for the study. Blood tests and fine-needle aspiration biopsy were performed to assess the thyroidal origin of the lesion, suspected to be a papillary thyroid carcinoma. A whole body SPECT/CT was performed 3 h after injection of 222 MBq of ^99mTc-HYNIC-TR1401 under deep anesthesia. The dog underwent surgery, the lesion was removed, and immunohistochemistry was performed using a rabbit anti-dog TSHR (LifeSpan Biosciences).

Results

Labeling of TR1401 with ^99mTc and quality controls

The highest labeling efficiency was obtained when the analogue was conjugated with a HYNIC:TR1401 ratio higher than 8:1. Determination of the molar substitution ratio of HYNIC-conjugated TR1401 demonstrated that an average of 1.9, 4.7, and 6.6 molecules of SHNH were bound per molecule of analogue, using a 4:1, 8:1, and a 12:1 HYNIC:TR1401 ratio respectively. The 8:1 ratio was selected for further experiments to avoid overconjugation of the hormone and possible structural modification (Fig. 1). Optimization of the labeling procedure of the HYNIC-TR1401 conjugate (40 μg) with ^99mTc showed that the use of 200 μl of tricine (1.1 mM) and 5 μl of SnCl₂ (50 nM), SnCl2:tricine ratio of 1:800, gave the highest LE (94±2%) and the lowest amount of colloids (<5%) after just 10 min of incubation (Fig. 1A). Specific activity of resulting ^99mTc-TR1401 was 7400 MBq/mg. Radiolabeled TR1401 was stable up to 24 h both in human serum and in a 0.9% NaCl solution at 37°C (Fig. 1B), as well as in solutions containing increasing cysteine concentrations (Fig. 1C). A slight decrease in the radiochemical purity was observed only at high cysteine concentrations (>1000:1). SDS-PAGE analysis of radiolabeled, conjugated, and unconjugated analogue showed no significant differences and the absence of significant degradation or aggregation resulting from conjugation and/or labeling (Fig. 1D).

FIG. 1.

In vitro quality controls of ^99mTc-HYNIC-TR1401. (A) Optimization of the TR1401 labeling protocol performed varying both SnCl₂ and tricine. Labeling efficiency (LE) of TR1401:HYNIC, 1:4 (continuous line) and 1:8 (dotted line) ratios did not vary significantly, whereas the amount of colloids of both 1:4 (dashed line) and 1:8 (semi-hashed-dotted line) ratios decreased with an increase of the SnCl₂:tricine ratio. (B) Stability of radiolabeled ^99mTc-HYNIC-TR1401 in saline (dashed line) and in plasma (straight line) over time assessed by instant thin-layer chromatography (ITLC). (C) Cysteine challenge assay of radiolabeled TR1401 assessed after 1 h of incubation by ITLC at increasing analogue:cysteine ratios. The labeled analogue shows excellent stability up to 10-fold molar excess of cysteine. (D) SDS-PAGE electrophoresis of unconjugated (1), conjugated (2), and radiolabeled (3) TR1401, performed in nonreducing conditions. On the left, a scan of the gel, for radioactivity detection, is shown. Native, conjugated, and labeled analogue bands co-migrate, and the radioactivity is associated with the only visible band of TR1401. (E) Binding, retention, and dissociation assay (decay-corrected) of radiolabeled TR1401 to/from ML-1 cells. The assay was performed using the LigandTracer^™ instrument and provided a K _d of 2.51 nM. (F) Binding assay of radiolabeled TR1401 on JP09 cells showing the total binding (straight line), specific binding (dashed line) and the nonspecific binding (dotted line). By nonlinear regression analysis, the calculated K _d is 8.79 nM.

Cell lines and FACS analysis

JP09, JP02, ML-1, and K1 showed excellent growth in vitro, although a progressive decrease of TSHR expression was noticed by JP09 cells in following passages. ML-1 cells had a very slow growing rate when injected in mice. Mean fluorescence intensity (range of MFI) was higher for K-1 cells (14.64–23.34), followed by ML-1 (6.93–7.99) and JP09 (5.59–8.93). JP02 cells showed a MFI<3, as expected, due to the absence of TSHR expression.

In vitro binding studies

ML-1 cells showed very fast radiopharmaceutical uptake, by LigandTracer, reaching a plateau within 20 min and a slow dissociation from the TSHR with time. The calculated K _d was 2.51 nM (Fig. 1E), and a retention experiment allowed us to determine that a third of the bound radioactivity was internalized, decreasing over time, with a half-life of 13.6±2 h. The binding assay performed with JP09 cells showed a K_d of 8.79 nM (Fig. 1F ) by nonlinear regression analysis.

In vivo high-resolution imaging

Visual analysis of images related to the biodistribution of ^99mTc-HYNIC-TR1401 in mice showed a rapid and persistent uptake by the kidneys and a moderate uptake by the liver with almost no signal from other organs and blood pool, as shown in Figure 2. Single organ counting revealed that thyroid uptake, even if low in absolute amounts compared to other major organs, is very high per gram of tissue and increases over time up to 6 h, with a decrease at 24 h (Fig. 3).

FIG. 2.

Planar posterior whole body images, at different time points, of nude CD1 mice after the injection of 370 Bq of TR1401. Images were acquired with a portable high-resolution mini-gamma camera and show the rapid and persistent kidney activity.

FIG. 3.

Single organ counts at 1 h (white bar), 3 h (squared bar), 6 h (dashed bar), and 24 h (black bar). Data are shown as % ID/g over time. Each point is the average of three mice. An evident uptake was found in the thyroid, kidneys, and liver.

Figure 4 shows the images acquired in mice injected with different cell lines in the right thigh. In animals injected with TSHR-positive cells, there is a focal uptake of the radiopharmaceutical where cells were injected. Regions of interest (ROIs) were drawn over the right and left thigh, and tumor/background (T/B) ratios were calculated at each time point (Fig. 5). All cell lines showed the highest T/B ratio at 3 h, and a slight decrease was observed at 6 h up to 24 h.

FIG. 4.

Planar posterior high-resolution camera (HRC) images of the legs of mice injected in the right thigh with TSHR-positive JP09 (A), JP02 TSHR-negative (B), ML-1 TSHR-positive (C), and K1 TSHR-positive (D) cells. Images were obtained 1, 3, 6, and 24 h after intravenous (i.v.) injection of ^99mTc-HYNIC-TR1401. The left thigh was injected with Matrigel only. Very high kidney uptake resulted in high counts in the bladder. The arrows indicate the right thigh and the site of cell injection. Images are not easily comparable due to different activity in the bladder, and therefore semi-quantitative analysis of the tumor/background (T/B) ratio is more reliable, as shown in (Figure 5.

FIG. 5.

T/B ratios calculated on planar posterior images obtained at 1, 3, 6, and 24 h after i.v. injection of ^99mTc-HYNIC-TR1401, by drawing a region of interest (ROI) over the injected cells and over the contralateral leg. JP09 (black bar), ML-1 (squared bar), K1 (dotted bar), and JP02 cells (white bar). The best T/B ratios were obtained at 3 h for all cell lines, confirming results of visual analysis of images and demonstrating the rapid uptake of this radiopharmaceutical with very fast plasma clearance.

Tumor xenografts in mice injected with JP09 and K1 cells were detectable after 20 days, and radiolabeled TR1401 was able to visualize the lesion with a high T/B ratio (6.8 and 2.9 respectively) as early as at 3 h after injection. No uptake was observed in tumors derived from TSHR negative cells (Fig. 6). ML-1 tumors were smaller and less vascularized than other tumors at autopsy. Images with ^99mTc-HYNIC-TR1401 showed the tumors best at 3 h after injection with a calculated T/B of 1.7.

FIG. 6.

Planar posterior HRC images of nude mice bearing a JP09 tumor in the right thigh and a JP02 tumor in the left thigh (A) or a K1 tumor (B) or a ML-1 tumor (C). To avoid the high kidney activity, images were also acquired of the lower part of the mouse as shown in the figure. There is tracer uptake in JP09 and K1 tumors, less uptake in the ML-1 tumor, and no uptake in the JP02 tumor (arrows).

Case study in a Dachshund dog with spontaneous thyroid cancer

The Dachshund dog was clinically symptom free, and routine hematologic and biochemical parameters were all within the reference ranges, including thyroxine and TSH levels. SPECT/CT images showed high uptake in the left thyroid lobe corresponding to the thyroid nodule with no significant uptake in the contralateral lobe (Fig. 7). No focal uptake was found in regional lymph nodes nor in other tissues, but it was found in the liver and kidneys as a consequence of ^99mTc-TR1401 metabolism. Despite the initial diagnosis, histologic examinations revealed that the excised lesion was a poorly differentiated thyroid cancer with high TSHR expression (Fig. 8).

FIG. 7.

(A) Single photon emission computed tomography (SPECT)/CT scan of a dog bearing a spontaneous thyroid tumor. CT scans (left column), SPECT scans (middle column), and fusion images (right column) are shown. Transaxial, coronal, and sagittal sections are shown the different rows. (B) High uptake of ^99mTc-HYNIC-TR1401 is clearly seen in the thyroid nodule (papillary cancer) in the left thyroid lobe, whereas negligible activity is detectable in the normal right thyroid lobe.

FIG. 8.

Histologic section of the excised lesion showing a poorly differentiated thyroid carcinoma (*) and the surrounding normal thyroid tissue (o). The section is stained with hematoxylin and eosin and with an anti-TSHR antibody specific for canine TSHR. The malignant tissue shows much higher density of TSHR expression compared to the normal tissue.

Discussion

Although ^99mTc-methoxyisobutylisonitrile (MIBI) scintigraphy (34), [¹⁸F]-FDG PET (13), radiolabeled somatostatin analogues (35), Doppler-US (36), contrast-enhanced magnetic resonance imaging (37), and others (38) have shown to be useful for the in vivo characterization of thyroid and extra-thyroid lesions, more accurate imaging techniques are needed.

We previously published an alternative approach for imaging differentiated thyroid cancers based on the use of a radiolabeled anti-Galectin-3 mAb (39). Despite the excellent results in preclinical studies, we had difficulties in translating this methodology to humans due to the murine nature of the antibody and the long plasma half-life of the labeled antibody that reduces T/B ratios and the possibility of detecting small lesions. A humanized antibody fragment radiolabeled with a positron-emitting isotope would have been more successful in humans. In the following years, we investigated, like others, the use of radiolabeled peptides and receptor agonist analogues.

Along this line, Sager et al. (40) investigated the role of scintigraphy with radiolabeled somatostatin analogues that showed a sensitivity ranging between 25% and 75% depending on patient selection criteria. They compared ¹⁸[F]-FDG and ^99mTc-MIBI with ^99mTc-HYNIC-TOC, preferring it to ¹¹¹In-octreotide due to its lower cost, higher resolution, and lower radiation dose to the patient. They found that the sensitivity of somatostatin receptor scintigraphy was higher than MIBI, but lower than ¹⁸[F]-FDG-PET. Similarly, Rodrigues et al. (41) proposed the use of ^99mTc-depreotide that showed, in many cases, a higher sensitivity than ¹⁸[F]-FDG-PET, but also nonspecific uptake in cells that play a role in granulomatous diseases, such as activated lymphocytes, leading to false-positive results.

Finally, Zhao et al. (42) proposed the use of the Arginine-Glycine-Aspartic acid (RGD) molecule 3PRGD2 labeled with ^99mTc that has a high affinity and specificity for integrin α_vβ_3, present in various malignant tumors. In 10 patients with negative ¹³¹I-WBS and high Tg, ^99mTc-3PRGD2 scintigraphy was able to visualize thyroid cancer metastases with a high T/B ratio that also correlated with growth rate. Moreover, the low background in the lungs facilitated the detection of metastases in the chest.

As an alternative to the above-mentioned imaging approaches, we have investigated the use of radiolabeled human TSH (43). Since the TSHR is overexpressed in some de-differentiated thyroid cancer, the relevance of this imaging approach depends on the potential of using this radiopharmaceutical not only for follow-up but also for preoperative staging of differentiated thyroid cancer. A further advantage of this technique could be the possibility of avoiding the induction of hypothyroidism either by thyroxine withdrawal or rhTSH administration.

We therefore radiolabeled rhTSH with ¹²³I and obtained interesting preclinical results. However, images obtained with ¹²³I-rhTSH were of relatively poor quality for three possible reasons: (a) the low specific activity of the radiopharmaceutical as a consequence of the low labeling efficiency of rhTSH with ¹²³I; (b) the low affinity binding of rhTSH to the TSHR; (c) the possible saturation of the TSHR by endogenous TSH. We therefore attempted to label rhTSH with ^99mTc with high specific activity and performed preliminary studies in animals and patients with metastatic thyroid cancer (unpublished data). However, tumor lesions were poorly distinguishable from background, and we explained these results by the low binding affinity of rhTSH to the TSHR.

This highlighted the need of searching for a new TSH analogue (TSH receptor agonist) with higher receptor binding affinity than rhTSH (44,45). The relatively low affinity of rhTSH, which is much lower than bovine or rodent TSH, is the result of an evolutionary change from an acute thermogenic hormone to one whose primary role in humans is to promote a gradual and chronic increase of NIS during periods of fasting or low iodine diet, as an adaptation to nomadic life (22,45). Recently, a novel second-generation superagonist rhTSH analogue named TR1401 has been produced and purified to homogeneity (>99%). It has very high in vitro receptor binding affinity and in vivo bioactivity (Trophogen, Inc., unpublished data). This new analogue has higher biopotency and maximal efficacy compared to standard wild-type hormone and first generation rhTSH analogues, and previous studies demonstrated its capacity to increase radioiodine and ¹⁸[F]-FDG uptake in FRTL-5 cells (22,46,47). Since the heterodimeric TSH molecule has crucial disulfide bonds, involved in the formation of a cysteine-knot in each subunit, we focused on the labeling of TR1401 with ^99mTc using an indirect method based on SHNH conjugation, obtaining a reliable and reproducible protocol that allowed us to radiolabel the analogue without affecting its biologic activity. SHNH is bound to lysine residues and then chelates the reduced technetium, thus avoiding opening the S–S bonds to insert Technetium, as this is done with the so-called direct methods (48).

Using the indirect method, tricine is used as a co-ligand, and its quantity, as well as that of SnCl₂, must be carefully selected in order to reduce ^99mTc-colloid formation and increase LE. We found that a SnCl₂:tricine ratio of 1:800 gave a 94% LE with negligible amounts of colloids (SA of 7400 MBq/mg). Labeled TR1401 was stable in both saline and human serum for up to 24 h and the binding on TSHR-positive cells was specific because in saturation binding assays performed on JP09 cells, an excess of unlabeled TR1401 was able to saturate the receptors and prevent further binding of labeled molecules. With ML-1 cells, a K _d of 2.51 nM was calculated.

This high affinity of TR1401 and the high specific activity of ^99mTc-TR1401 allowed us to inject relatively low doses of the radiopharmaceutical into the animals and obtain excellent tumor localization by gamma camera imaging. This could also be achieved in humans, thus reducing the radiation dose and any biologic effect on TSHR positive tumors.

In mice, the radiolabeled analogue showed early targeting to tumors and the thyroid, as well as fast renal metabolism with very low blood pool activity at late time points.

The thyroid showed, ex vivo, the highest % ID/g, even if it could not be clearly visualized with the mini-gamma camera because of its small size, which was below its resolution. JP09 tumors were visualized in vivo with a high T/B ratio (6.8) at 3 h, whereas K1 and ML-1 tumors showed a lesser uptake (2.9 and 1.7 respectively, both at 3 h). It should be mentioned that T/B values did not quantitatively correlate with the TSHR density calculated by FACS analysis. Our interpretation of these results is based on the consideration that cells in xenografts behave very differently from cultures, and the vascularization of xenografts may also vary and affect the uptake of radiopharmaceutical. Thus, ML-1 tumors were slow growing, small, and poorly vascularised. K1 tumors grew well but differ from ML-1 and JP09 because of their origin. The case study in a Dachshund dog with a spontaneous poorly differentiated thyroid cancer, although not fully conclusive, is of interest because it highlights the potential of this new radiopharmaceutical for detection of intrathyroidal lesions. SPECT/CT images performed 3 h after i.v. injection confirmed that TR1401 rapidly binds in vivo to tumor cells, with a very low blood pool activity and predominant kidney accumulation observed previously for highly sialylated rhTSH preparations (47). The clear visualization of the tumor within the thyroid gland in euthyroid conditions suggests the possibility of using this radiopharmaceutical for preoperative TSHR-based staging in addition to patient follow-up and for imaging de-differentiated thyroid cancer metastases. Indeed, we can assume that the lower the level of endogenous TSH, the better the condition for using radiolabeled TR1401 because of a decreased likelihood of competition at the TSHR. However, radiolabeled TR1401 affinity for the human TSHR is much higher than that of wild-type hTSH, and suppression of endogenous TSH will most likely not be necessary in patients.

Because of this favorable biodistribution, high binding affinity, and retention in the cytoplasm, radiolabeled-TR1401 could also be suitable for therapeutic purposes, if radiolabeled with a beta-emitting isotope such as ¹⁷⁷Lu, providing the ability to perform a renal protection by amino acid infusion, as for other radiolabeled peptides (49). Moreover, novel long-acting superagonist rhTSH analogues are under development and may replace the high renal uptake of TR1401. From a therapeutic point of view, ^99mTc-TR1401 could be useful to predict which radioiodine-negative thyroid cancers might respond to therapies with ¹⁷⁷Lu-labeled TSH analogues, which are currently under development in our laboratory and at Trophogen.

The relative role of ^99mTc-TR1401 versus ¹³¹I scanning of thyroid cancer will require future histopathologic and clinical studies in patients receiving both scanning modalities, since the in vivo functional status of the TSHR versus NIS has not yet been clarified. Therefore, it would be important to understand which patients may benefit from such novel radiopharmaceuticals, and whether ^99mTc-TR1401 scintigraphy could become complementary to radioiodine scanning in the management of differentiated thyroid cancer patients. As a minimum, ^99mTc-TR1401 scanning will provide a major new unmet clinical need to image thyroid cancers that have lost the expression or membrane insertion of NIS while retaining expression of functional TSHRs. These thyroid cancers are typically associated with finding a positive serum Tg and a negative iodine scan, thus posing a major diagnostic and therapeutic challenge. The fact that most of these patients respond with an increase in serum Tg to endogenous or rhTSH proves that they retain an appreciable numbers of TSHRs that allow cancer imaging with the new high affinity TSH analogue. In addition, even in cancers with a functional NIS and TSHR overexpression, ^99mTc-TR1401 may have advantages for imaging of intrathyroidal cancers, or local nodes in presurgical staging and distant metastases, allowing physicians to perform the scintigraphy before thyroidectomy without interference of the thyroid. This would allow the surgeon to remove local non-iodine uptaking nodes at the moment of the thyroidectomy. Our study, as a proof of concept, opens new diagnostic and therapeutic strategies.

Conclusions

The highly pure rhTSH superagonist TR1401 was efficiently labeled with ^99mTc with high specific activity and used for imaging TSHR-positive cell lines in vitro and TSHR-positive thyroid tumor xenografts in mice. A spontaneous poorly differentiated thyroid cancer within the thyroid was also imaged in a dog. In the light of these results, we will investigate the possibility of using this radiopharmaceutical for imaging intrathyroidal differentiated thyroid cancer and, particularly, radioiodine-negative metastases.

Due to fast in vivo binding of ^99mTc-HYNIC-TR1401, a possible use of short half-life positron emitting isotopes can also be considered (such as ¹⁸F or ⁶⁸Ga) for PET/CT imaging. More studies are necessary to evaluate the possibility of labeling TR1401 with a beta-emitting isotope for therapeutic purposes.

Footnotes

Acknowledgments

We wish to acknowledge Drs. Meng Zhang and Vladimir Wolf for their contributions at Trophogen, Inc., to the development, production, purification, and initial characterization of purified TR1401 analogue glycoprotein. Dr. Armando Bartolazzi performed the immunohistochemical staining of dog tissues. Funding for this project was provided in part by Trophogen, Inc., NIH-SBIR Grant R43DK076302, AIRC IG Grant 2010 10359, AIRC IG-13234 and “Sapienza” University research project C26A10H3AN. We also wish to acknowledge the nonprofit association Nuclear Medicine Discovery for support.

Author Disclosure Statement

B.W., M.S., and V.F. are employed by Trophogen, Inc. F.G., I.M., G.P., L.B., R.D., and A.S. have no competing financial interests.

References

Elisei

, Pinchera

, Romei

, Gryczynska

, Pohl

, Maenhaut

, Fugazzola

, Pacini

. 1994. Expression of thyroytopin receptor (TSH-R), thyroglobulin, thyroperoxidase and calcitonin messenger ribonucleic acid in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. J Clin Endocrinol Metab, 78:867–871.

Clark

, Castner

. 1979. Thyrotropin “receptors” in normal and neoplastic human thyroid tissue. Surgery, 85:624–632.

Szkudlinski

, Fremont

, Ronin

, Weintraub

. 2001. Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol Rev, 82:473–502.

Morris

, Myssiorek

. 2010. Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg, 200:454–461.

Lazar

, Bidart

, Caillou

, Mahé

, Lacroix

, Filetti

, Schlumberger

. 1999. Expression of the Na+/I− symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab, 84:3228–3234.

Maffioli

, Florimonte

, Fugazzola

, Banti

, Bagnasco

, Dottorini

, Perotti

, Rubello

, Seregni

, Bombardieri

, Testori

. 2012. The widened use of exogenous stimulation with recombinant human TSH to treat metastatic thyroid carcinoma in Italy 2012. Q J Nucl Med Mol Imaging, 56:476–484.

Schlumberger

, Torlantano

. 2000. Papillary and follicular thyroid carcinoma. Baillieres Best Pract Res Clin Endocrinol Metab, 14:601–613.

Ladenson

, Braverman

, Mazzaferri

, Brucker-Davis

, Cooper

, Garber

, Wondisford

, Davies

, DeGroot

, Daniels

, Ross

, Weintraub

. 1997. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. New Engl J Med, 337:888–896.

Capoccetti

, Criscuoli

, Rossi

, Ferretti

, Manni

, Brianzoni

. 2009. The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer. Q J Nucl Med Mol Imaging, 53:536–545.

10.

Phan

, Jager

, Paans

, Plukker

, Sturkenboom

, Sluiter

, Wolffenbuttel

, Dierckx

, Links

. 2008. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging, 35:958–965.

11.

Pettinato

, Monari

, Nanni

, Allegri

, Marcatili

, Civollani

, Cima

, Spezi

, Mazzarotto

, Fanti

. 2012. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I. Q J Nucl Med Mol Imaging, 56:509–514.

12.

Helal

, Merlet

, Toubert

, Franc

, Schvartz

, Gauthier-Koelesnikov

, Prigent

, Syrota

. 2001. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med, 42:1464–1469.

13.

Piccardo

, Foppiani

, Morbelli

, Bianchi

, Barbera

, Biscaldi

, Altrinetti

, Villavecchia

, Cabria

. 2011. Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive 131I whole body scan?. Q J Nucl Med Mol Imaging, 55:57–65.

14.

Giuffrida

, Prestifilippo

, Scarfia

, Martino

, Marchisotta

. 2012. New treatment in advanced thyroid cancer. J Oncol, 2012:391629.

15.

Leboulleux

, Schroeder

, Busaidy

, Auperin

, Corone

, Jacene

, Ewertz

, Bournaud

, Wahl

, Sherman

, Ladenson

, Schlumberger

. 2009. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab, 94:1310–1316.

16.

Middendorp

, Selkinski

, Happel

, Kranert

, Grünwald

. 2010. Comparison of positron emission tomography with [18F]FDG and [68Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data. Q J Nucl Med Mol Imaging, 54:76–83.

17.

Heston

, Wahl

. 2010. Molecular imaging in thyroid cancer. Cancer Imaging, 10:1–7.

18.

De Araujo-Filho

, Alves

, de Castro

, Lourenço

, Cernea

, Brandão

, Ferraz

. 2009. Vascular endothelial growth factor expression in invasive papillary thyroid carcinoma. Thyroid, 19:1233–1237.

19.

Wong

, Dvorak

, Marzola

, Grassetto

, Gross

, Rubello

. 2011. Molecular imaging in the management of thyroid cancer. Q J Nucl Med Mol Imaging, 55:541–559.

20.

Ciampi

, Vivaldi

, Romei

, Del Guerra

, Salvadori

, Cosci

, Pinchera

, Elisei

. 2008. Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Mol Cell Endocrinol, 291:57–62.

21.

Mueller

, Kleinau

, Szkudlinski

, Jaeschke

, Krause

, Paschke

. 2009. The superagonistic activity of bovine thyroid-stimulating hormone (TSH) and the human TR1401 TSH analog is determined by specific amino acids in the hinge region of the human TSH receptor. J Biol Chem, 284:16317–16324.

22.

Szkudlinski

, Teh

, Grossmann

, Tropea

, and Weintraub

. 1996. Engineering human glycoprotein hormone superactive analogues. Nat Biotechnol, 14:1257–1263.

23.

Leitolf

, Tong

, Grossmann

, Weintraub

, Szkudlinski

. 2000. Bioengineering of human thyrotropin superactive analogs by site-directed “lysine-scanning” mutagenesis. Cooperative effects between peripheral loops. J Biol Chem, 275:27457–27465.

24.

Gallagher

. 2012. One-dimensional SDS gel electrophoresis of proteins. Curr Protoc Protein Sci, Chapter 10:Unit 10.1.1–44.

25.

Wallaschofski

, Paschke

. 1999. Detection of thyroid stimulating (TSAB)- and thyrotropin stimulation blocking (TSBAB) antibodies with CHO cell lines expressing different TSH-receptor numbers. Clin Endocrinol (Oxf ), 50:365–372.

26.

Ludgate

, Costagliola

, Danguy

, Perret

, Vassart

. 1992. Recombinant TSH-receptor for determination of TSH-receptor-antibodies. Exp Clin Endocrinol, 100:73–74.

27.

Schönberger

, Bauer

, Spruss

, Weber

, Chahoud

, Eilles

, Grimm

. 2000. Establishment and characterization of the follicular thyroid carcinoma cell line ML-1. J Mol Med (Berl), 78:102–110.

28.

Wyllie

, Haughton

, Rowson

, Wynford-Thomas

. 1999. Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53. British Journal of Cancer, 79:1111–1120.

29.

Bjorke

, Andersson

. 2006. Automated, high-resolution cellular retention and uptake studies in vitro. Appl Radiat Isot, 64:901–905.

30.

Harper

, Juliano

. 1980. Isolation and characterization of Chinese hamster ovary cell variants defective in adhesion to fibronectin-coated collagen. J Cell Biol, 87:755–763.

31.

Chianelli

, Signore

, Fritzberg

, Mather

. 1997. The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl Med Biol, 24:579–586.

32.

Soluri

, Massari

, Trotta

, Montani

, Iurlaro

, Mangano

, Scopinaro

, Scafè

. 2005. New imaging probe with crystals integrated in the collimator's square holes. Nucl Instrum Methods Phys Res A, 554:331–339.

33.

Malviya

, de Vries

, Dierckx

, Signore

. 2011. Synthesis and evaluation of 99mTc-labelled monoclonal antibody 1D09C3 for molecular imaging of major histocompatibility complex class II protein expression. Mol Imaging Biol, 13:930–939.

34.

Campennì

, Violi

, Ruggeri

, Sindoni

, Moleti

, Vermiglio

, Baldari

. 2010. Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer. Nucl Med Commun, 31:274–279.

35.

Pazaitou-Panayiotou

, Tiensuu Janson

, Koletsa

, Kotoula

, Stridsberg

, Karkavelas

, Karayannopoulou

. 2012. Somatostatin receptor expression in non-medullary thyroid carcinomas. Hormones (Athens), 11:290–296.

36.

Carneiro-Pla

. 2013. Ultrasound elastography in the evaluation of thyroid nodules for thyroid cancer. Curr Opin Oncol, 25:1–5.

37.

Yuan

, Yue

, Tao

. 2012. The diagnostic value of dynamic contrast-enhanced MRI for thyroid tumors. Eur J Radiol, 81:3313–3318.

38.

Boufraqech

, Patel

, Xiong

, Kebebew

. 2013. Diagnosis of thyroid cancer: state of art. Expert Opin Med Diagn, 7:331–342

39.

Bartolazzi

, D'Alessandria

, Parisella

, Signore

, Del Prete

, Lavra

, Braesch-Andersen

, Massari

, Trotta

, Soluri

, Sciacchitano

, Scopinaro

. 2008. Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3. PLoS One, 3:e3768.

40.

Sager

, Kabasakal

, Halac

, Maecke

, Uslu

, Önsel

, Kanmaz

. 2013. Comparison of 99mTc-HYNIC-TOC and HYNIC-TATE octreotide scintigraphy with FDG PET and 99mTc-MIBI in local recurrent or distant metastatic thyroid cancers. Clin Nucl Med, 38:321–325.

41.

Rodrigues

, Li

, Gabriel

, Heute

, Greifeneder

, Virgolini

. 2006. 99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer. J Clin Endocrinol Metab, 91:3997–4000.

42.

Zhao

, Jin

, Li

, Liang

, Lin

. 2012. Integrin αvβ3 imaging of radioactive iodine-refractory thyroid cancer using 99mTc-3PRGD2. J Nucl Med, 53:1872–1877.

43.

Corsetti

, Chianelli

, Cornelissen

, Van de Wiele

, D'Alessandria

, Slegers

, Mather

, Di Mario

, Filetti

, Scopinaro

, Signore

. 2004. Radioiodinated recombinant human TSH: a novel radiopharmaceutical for thyroid cancer metastases detection. Cancer Biother Radiopharm, 19:57–63.

44.

Willey

. 1999. An elusive role for glycosylation in the structure and function of reproductive hormones. Hum Reprod Update, 5:330–355.

45.

Szkudlinski

, Grossmann

, Leitolf

, Weintraub

. 2000. Human thyroid-stimulating hormone: structure-function analysis. Methods, 21:67–81.

46.

Reinfelder

, Maschauer

, Foss

, Nimmagadda

, Fremont

, Wolf

, Weintraub

, Pomper

, Szkudlinski

, Kuwert

, Prante

. 2011. Effects of recombinant human thyroid-stimulating hormone superagonists on thyroidal uptake of 18F-fluorodeoxyglucose and radioiodide. Thyroid, 21:783–792.

47.

Szkudlinski

, Thotakura

, Tropea

, Grossmann

, Weintraub

. 1995. Asparagine linked oligosaccharide structures determine clearance and organ distribution of pituitary and recombinant thyrotropin. Endocrinology, 136:3325–3330.

48.

Mather

, Ellison

. 1990. Reduction-mediated technetium-99m labeling of monoclonal antibodies. J Nucl Med, 31:692–697.

49.

Bodei

, Ferone

, Grana

, Cremonesi

, Signore

, Dierckx

, Paganelli

. 2009. Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Investig, 32:360–369.

99m Tc-Labeled-rhTSH Analogue (TR1401) for Imaging Poorly Differentiated Metastatic Thyroid Cancer

Abstract

Background:

Methods:

Results:

Conclusions:

Introduction

Materials and Methods

Labeling of superagonist rhTSH analogue TR1401 with 99mTc

In vitro quality controls

Cell lines and FACS analysis

In vitro binding studies

In vivo high-resolution imaging

Case study in a Dachshund dog with spontaneous thyroid cancer

Results

Labeling of TR1401 with 99mTc and quality controls

Cell lines and FACS analysis

In vitro binding studies

In vivo high-resolution imaging

Case study in a Dachshund dog with spontaneous thyroid cancer

Discussion

Conclusions

Footnotes

Acknowledgments

Author Disclosure Statement

References

Labeling of superagonist rhTSH analogue TR1401 with ^99mTc

Labeling of TR1401 with ^99mTc and quality controls